Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Variants in MARC1 and HSD17B13 reduce severity of NAFLD in children, perturb phospholipid metabolism, and suppress fibrotic pathways

Christian A. Hudert, Anna Alisi, Quentin M. Anstee, Annalisa Crudele, Laura G. Draijer, EU-PNAFLD investigators, Samuel Furse, Jan G. Hengstler, Benjamin Jenkins, Kylie Karnebeek, Deirdre A. Kelly, Bart G. Koot, Albert Koulman, David Meierhofer, Stuart G. Snowden, Indra van Mourik, Anita Vreugdenhil, Susanna Wiegand, View ORCID ProfileJake P. Mann
doi: https://doi.org/10.1101/2020.06.05.20120956
Christian A. Hudert
1Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Alisi
2Research Unit of Molecular Genetics of Complex Phenotypes, Bambino Gesù Children’s Hospital-IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quentin M. Anstee
3Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
4Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annalisa Crudele
2Research Unit of Molecular Genetics of Complex Phenotypes, Bambino Gesù Children’s Hospital-IRCCS, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura G. Draijer
5Department of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Center, Emma Children’s Hospital, University of Amsterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Furse
6Core Metabolomics and Lipidomics Laboratory, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan G. Hengstler
7Systems Toxicology, Leibniz Research Centre for Working Environment and Human Factors at the Technical University Dortmund, Dortmund, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Jenkins
6Core Metabolomics and Lipidomics Laboratory, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kylie Karnebeek
8Center for Overweight Adolescent and Children’s Health Care (COACH), Department of Pediatrics, Maastricht University Medical Center, Maastricht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deirdre A. Kelly
9Liver Unit, Birmingham Women’s and Children’s Hospital Trust, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart G. Koot
5Department of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Center, Emma Children’s Hospital, University of Amsterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Koulman
6Core Metabolomics and Lipidomics Laboratory, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Meierhofer
10Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart G. Snowden
6Core Metabolomics and Lipidomics Laboratory, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Indra van Mourik
9Liver Unit, Birmingham Women’s and Children’s Hospital Trust, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Vreugdenhil
8Center for Overweight Adolescent and Children’s Health Care (COACH), Department of Pediatrics, Maastricht University Medical Center, Maastricht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanna Wiegand
11Center for chronically sick children, Charite Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jake P. Mann
12Institute of Metabolic Science, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jake P. Mann
  • For correspondence: jm2032{at}cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background & aims Genome-wide association studies in adults have identified variants in HSD17B13 and MARC1 as protective against NAFLD. It is not known if they are similarly protective in children and, more generally, whether the peri-portal inflammation of pediatric NAFLD and lobular inflammation seen in adults share common genetic influences. Therefore, we aimed to: establish if these variants are associated with NAFLD in children, and to investigate the function of these variants in hepatic metabolism using metabolomics.

Methods 960 children (590 with NAFLD, 394 with liver histology) were genotyped for rs72613567T>TA in HSD17B13, rs2642438G>A in MARC1. Genotype-histology associations were tested using ordinal regression. Untargeted hepatic proteomics and plasma lipidomics were performed in a subset of samples. In silico tools were used to model the effect of rs2642438G>A (p.Ala165Thr) on MARC1.

Results rs72613567T>TA in HSD17B13 was associated with lower odds of NAFLD diagnosis (OR 0.7 (95%CI 0.6-0.9) and lower grade of portal inflammation (P<0.001) whilst rs2642438G>A in MARC1 was associated with lower grade of hepatic steatosis (P=0.02). Proteomics found reduced expression of HSD17B13 in carriers of the protective allele, whereas MARC1 levels were not affected by genotype. Both variants showed downregulation of hepatic fibrotic pathways, upregulation of retinol metabolism and perturbation of phospholipid species. Modelling suggests that p.Ala165Thr would disrupt the stability and metal-binding of MARC1.

Conclusions There are shared genetic mechanisms between pediatric and adult NAFLD, despite their differences in histology. MARC1 and HSD17B13 are involved in phospholipid metabolism and suppress fibrosis in NAFLD.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Clintrials.gov NCT04190849

Funding Statement

CAH, DM and SW are supported by the German Systems Biology Program (LiSyM - grant no. 31L0057 and 31L0058) sponsored by the German Federal Ministry of Education and Research (BMBF). JPM is supported by a Wellcome Trust fellowship (216329/Z/19/Z), a European Society for Paediatric Research (ESPR) Young Investigator Award, and a Childrens Liver Disease Foundation Grant. EU-PNAFLD Registry is supported by an European Association for Study of the Liver (EASL) Registry Grant and by the Newcastle NIHR Biomedical Research Centre/Newcastle University using a database infrastructure developed by the EU EPoS consortium. AA is supported by grant from Italian Ministry of Health (5x1000). SF was supported by funding form BBSRC (BB/M027252/1, original proposal written by AK). BK is supported by grants from Van den Broek Lohman Foundation, Virtutis Opus Foundation and For Wishdom Foundation. QMA in a Newcastle NIHR Biomedical Research Centre investigator and a member of the EU H2020 EPoS (Elucidating Pathways of Steatohepatitis) and EU IMI2 LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortia funded under grant agreements 634413 and 777377 respectively.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

East Midlands - Nottingham 2 Research Ethics Committee (17/EM/0084) Maastricht University Medical Centre (under ethical approval METC 13-4-130) Amsterdam University Medical Centre (under ethical approval MEC 2017_306 and MEC 07/141) Bambino Gesu hospital (protocol number 1774_OPBG_2019) Charite Berlin (under ethical approval of the local institutional review board EA2/049/14).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Full summary statistics available in Data Supplement.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted June 07, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Variants in MARC1 and HSD17B13 reduce severity of NAFLD in children, perturb phospholipid metabolism, and suppress fibrotic pathways
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Variants in MARC1 and HSD17B13 reduce severity of NAFLD in children, perturb phospholipid metabolism, and suppress fibrotic pathways
Christian A. Hudert, Anna Alisi, Quentin M. Anstee, Annalisa Crudele, Laura G. Draijer, EU-PNAFLD investigators, Samuel Furse, Jan G. Hengstler, Benjamin Jenkins, Kylie Karnebeek, Deirdre A. Kelly, Bart G. Koot, Albert Koulman, David Meierhofer, Stuart G. Snowden, Indra van Mourik, Anita Vreugdenhil, Susanna Wiegand, Jake P. Mann
medRxiv 2020.06.05.20120956; doi: https://doi.org/10.1101/2020.06.05.20120956
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Variants in MARC1 and HSD17B13 reduce severity of NAFLD in children, perturb phospholipid metabolism, and suppress fibrotic pathways
Christian A. Hudert, Anna Alisi, Quentin M. Anstee, Annalisa Crudele, Laura G. Draijer, EU-PNAFLD investigators, Samuel Furse, Jan G. Hengstler, Benjamin Jenkins, Kylie Karnebeek, Deirdre A. Kelly, Bart G. Koot, Albert Koulman, David Meierhofer, Stuart G. Snowden, Indra van Mourik, Anita Vreugdenhil, Susanna Wiegand, Jake P. Mann
medRxiv 2020.06.05.20120956; doi: https://doi.org/10.1101/2020.06.05.20120956

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)